Mouse model of cancer can be used to:
Study the intrinsic mechanisms involved in tumorigenesis, tumor progression and metastasis
Evaluate the efficacy of cancer immunotherapies
Serve for preclinical screening of anti-cancer agents
Shanghai Model Organisms Center offers a variety of mouse models of cancer to meet the needs of both academic and industry partners.
Genetically-engineered mouse model (GEMM)
Genetically engineered mouse models with spontaneously arising tumors. GEMM have been developed in SMOC to mimic the genetic events observed in human cancer genesis and development, with transgenic, knock-in, or knock-out models based upon well-characterized oncogenes or tumor suppressors.
The main features of GEMM include fully competent murine immunity and comprehensive mouse stroma that is known to directly affect tumor response to therapy. Besides, there is usually a clear molecular pathogenesis of disease around specific mutated genetic features, which makes GEMM an ideal tool for investigating the underlying mechanisms of tumorigenesis.
In general, GEMM cancer models are established using the following two strategies:
Oncogene overexpression or introduction of disease-causing mutations
A few examples include Myc conditional overexpression, Apcmin, Kras(G12D), etc.
Loss of tumor suppressor gene function
Cancer cell line-derived xenograft (CDX) model
Cancer cell line-derived xenograft (CDX) model is a well-established mouse model type commonly used for cancer research and anti-tumor drug development, due to its user-friendly techniques and outstanding repeatability. In CDX models, cancer cells are inoculated into immuno-deficient mice via various routes. Available recipient mice include Balb/c nude mice, NOD-scid or other immunodeficient mice.
Figure: A549-mediated subcutaneous tumor formation on NMG mice.
Patient-derived Xenografts (PDX) are advanced preclinical oncology model for drug development. It offers a far better alternative for preclinical drug evaluation as compared to the conventional cell line-derived xenograft model.
By maintaining genotypic and phenotypic diversity of patient tumor tissues, PDX is capable of capturing a more faithful representation of the human tumor's characteristics.
PDX preserves tumor stroma and tumor microenvironments.
Compared with cancer cell lines, PDX offers a more faithful representation of the mechanisms of tumor genesis and development.
Compared with cancer cell lines, PDX offers a better reflection of cancer patients' drug sensitivity and tolerance levels during drug screening.
Screening and biomarker development of anti-cancer drugs
Co-clinical trials of anti-cancer drugs
Study on tumor mechanisms
Having successfully established more than 60 types of liver cancer PDX models, Shanghai Model Organisms has identified their key characteristics through the analysis of genomics, histopathology, growth characteristics, drug responses to standard treatments, etc. Our research has demonstrated that PDX is capable of replicating the heterogeneity of patient tumors in various aspects, including their molecular, genetic and histological complexities. Our range of PDX models allows highly-efficient testing and analysis of drug efficacy in different clinical settings. PDX tumors collected from our PDX models can also be used in preclinical trials to facilitate drug development by mimicking Phase II patient tumor sizes.
Fig 1. Tumor growth curves of liver cancer PDX models after treatment with different drug groups.
Carcinogen-induced mouse model
Diethylnitrosamine (DEN) is highly toxic to humans and animals. The injection or oral administration of the smallest quantities of DEN can result in severe liver damage. Due to its consistency in inducing hepatic lesions in rodents, DEN is commonly used to generate rodent models of hepatocellular carcinoma (HCC). Mice develop liver damage after DEN administration, which leads to cirrhosis and tumors. Hence the DEN mouse model is one of the ideal models for the research on the pathogenesis of hepatic cancer.
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.詳細
After the base is put into operation, SMOC’s capability to provide genetically modified rat/mouse models and technical services including gene function research and drug development will be greatly enhanced.詳細